...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anti-cancer drugs >Prolonged administration of infusional cisplatin and oral etoposide in advanced non-small cell lung cancer.
【24h】

Prolonged administration of infusional cisplatin and oral etoposide in advanced non-small cell lung cancer.

机译：在晚期非小细胞肺癌中长期服用顺铂和口服依托泊苷。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We conducted a phase I/II trial to determine the maximum tolerated dose (MTD) and the efficacy of prolonged infusion of cisplatin and oral etoposide in the treatment of advanced non-small cell lung cancer (NSCLC). Cisplatin was given via an infuser in escalating doses of 5, 6.5, 8, 9 and 10 mg/m /day for 14 days along with etoposide at a fixed dose of 50 mg/m /day orally followed by a 2-week rest period. All patients had stage IIIB or IV NSCLC. A cisplatin dose of 8 mg/m /day was determined as the MTD. In the 13 patients treated at this dose level, grade III and IV toxicities were mainly hematologic including neutropenia ( =5), febrile neutropenia ( =4), thrombocytopenia ( =3) and anemia ( =6). Grade III/IV renal toxicity occurred in one patient. There were no treatment-related deaths. One patient had a partial response and three patients had stable disease. Thus, although the described regimen of cisplatin/etoposide is reasonably well tolerated, it does not appear to be better than the same combination administered over a shorter duration, in spite of a cumulative dose of 112 mg/ m of cisplatin and 700 mg/ m of etoposide per cycle.
机译：我们进行了I / II期试验，以确定最大耐受剂量（MTD）以及长期输注顺铂和口服依托泊苷对晚期非小细胞肺癌（NSCLC）的疗效。顺铂以5，6.5、8、9和10毫克/米2 /天的剂量递增，连续14天服用依托泊苷，口服固定剂量为50毫克/米2 /天，随后为期2周的休息时间。所有患者均患有IIIB或IV期NSCLC。将8 mg / m 2 /天的顺铂剂量确定为MTD。在以该剂量水平治疗的13例患者中，III和IV级毒性主要是血液学的，包括中性粒细胞减少症（= 5），发热性中性粒细胞减少症（= 4），血小板减少症（= 3）和贫血（= 6）。一名患者发生III / IV级肾毒性。没有与治疗有关的死亡。一名患者有部分反应，三名患者病情稳定。因此，尽管所描述的顺铂/依托泊苷方案被合理地耐受，但尽管累积剂量为112 mg / m顺铂和700 mg / m，它似乎并不比在较短时间内给予的相同组合更好。每个周期的依托泊苷含量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号